Delivery Order SPE2DB22D2005-SPE2DB25FJQF2
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on September 5, 2025, for the supply of Ibrance 75 mg tablets in quantities of seven units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $8,123.96 and is scheduled for completion by September 26, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents no set-aside designation....
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets in quantities of seven units. This firm fixed price delivery order, valued at $32,489.92, represents a competitive award with no set-aside designation and is scheduled for completion by September 24, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7s) on August 26, 2025, with an ultimate completion date of September 17, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ibrance 125 mg tablets on July 17, 2025, with an ultimate completion date of August 7, 2025. This competitively awarded, non-set-aside contract calls for delivery to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ibrance 125 mg tablets (7-count) under a firm fixed-price contract with a ceiling value of $8,118.08 and an ultimate completion date of September 8, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 for the supply of Ibrance 100 mg tablets (7-day supply) under a firm fixed price contract. The award was made on August 5, 2025, with an ultimate completion date of August 26, 2025. This is an unset-aside, competitively awarded delivery order executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibrance 100 mg tablets (quantity 7s) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with a completion date of September 30, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The U.S. Defense Department's Medical Supply Chain awarded a $32,495.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg tablets (7-count units) on September 23, 2025, with completion targeted for October 15, 2025. The award was issued on a non-competitive basis as a delivery order under an existing contract vehicle. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 75 mg tablets in quantities of seven units, with a contract ceiling value of $8,123.96. This competitively awarded, firm fixed-price delivery order is set to be completed by September 24, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJQF2Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Ibrance 125 mg tablets in a 7-tablet configuration. This contract, valued at $8,118.08 with a firm fixed price structure, represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 12, 2025. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen supplies an extensive portfolio of brand-name and generic medications to federal medical procurement needs, particularly for military and veteran healthcare systems. The DLA Medical Supply Chain relies on such prime vendors to deliver critical pharmaceutical commodities across multiple therapeutic domains. This award demonstrates the contractor's continued capability to fulfill federal medical supply requirements through open competition and reflects its role as a key vendor supporting Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible contract vehicles designed to meet evolving military healthcare demands.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 7/22/25 |